Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-muscarinic 3 antibodies associate with a severe clinical phenotype in patients with systemic sclerosis.

Rheumatology (Oxford, England) - 1 Oct 2025

Ayla Ali Y, Kalavar Naveen R, Pimentel Mark, Morales Walter, Hummers Laura K, Shah Ami A, Hughes Michael, McMahan Zsuzsanna H

Abstract excerpt

OBJECTIVES: Functional antibodies play a role in SSc gastrointestinal (GI) disease, but their clinical relevance is unclear. We examined GI and extraintestinal features associated with anti-muscarinic-3 receptor (M3R) antibodies in SSc patients. METHODS: In a cohort enriched for GI symptoms, SSc patients were tested for anti-M3R antibodies using an ELISA. High-titres were defined a priori based on the top...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Antinuclear
Share to Autoantibodies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Relevance

Share to Enzyme-Linked Immunosorbent Assay

Share to Gastrointestinal Diseases

Share to Logistic Models

Share to Receptor, Muscarinic M3

Share to Scleroderma, Systemic

Source

Open in PubMed Open full text

Identifiers

PMID: 40220335
DOI: 10.1093/rheumatology/keaf197
PMCID: PMC12494224

Genes

RNPC3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-muscarinic 3 antibodies associate with a severe clinical phenotype in patients with systemic sclerosis.PMID 40220335Read ↗

Objective gastrointestinal involvement in patients with systemic sclerosis: Prevalence and clinico-immunological phenotypes in the REMSCLE registry.Semantic proximity Read ↗

Novel autoantibodies in patients with systemic sclerosis and gastrointestinal dysfunction provide insight into disease pathogenesisSemantic proximity Read ↗

Anti-Gephyrin antibodies: A novel specificity in patients with systemic sclerosis and lower bowel dysfunctionSemantic proximity Read ↗

Proteome-wide serology reveals immune-defined subtypes of gastrointestinal disease in systemic sclerosisSemantic proximity Read ↗

Determining the Risk Factors and Clinical Features Associated With Severe Gastrointestinal Dysmotility in Systemic Sclerosis.Semantic proximity Read ↗

Antivinculin Antibodies in Systemic Sclerosis: Associations With Slow Gastric Transit and Extraintestinal Clinical Phenotype.Semantic proximity Read ↗

Serum markers of microbial translocation and intestinal damage in assessment of gastrointestinal tract involvement in systemic sclerosisSemantic proximity Read ↗

Distinct clinical trajectories of gastrointestinal progression among patients with systemic sclerosis.Semantic proximity Read ↗

The Gut-Heart Axis in Systemic Sclerosis: Evidence from the GENISOS cohortSemantic proximity Read ↗

PPI-Refractory GERD in Systemic Sclerosis Is Driven by Distinct Esophageal and Gastric Motility AbnormalitiesSemantic proximity Read ↗

Oesophageal dysmotility patterns are associated with distinct clinical phenotypes and prognosis in patients with systemic sclerosis.Semantic proximity Read ↗

Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.